FOR IMMEDIATE RELEASE

Contact: Sharon Phillips

Phone: 1-954-575-4973

Cell: 1-954-540-1896

Twitter: HBOT 2010

Email: Sharon@hbot2010.net

or visit: www.hbot2010.net

INTERNATIONAL MEDICAL SYMPOSIUM “HBOT 2010” SET FOR IRVINE MARRIOTT, JULY 22-25

Monday, June 7th, Newport Beach, CA: Physicians and medical practitioners from around the globe will gather at the Irvine Marriott Hotel July 22-25, for “HBOT 2010”, an educational symposium, of world-wide medical significance.

Their focus will be on the healing and life sustaining benefits of oxygen, in the treatment of serious medical conditions. New to this year’s symposium will be the latest information on the treatment of war veterans with blast injuries, as well as cutting edge information on HBOT’s use for people with cancer and diabetes.

Hyperbaric Oxygenation Therapy Treatment, (known as HBOT), originated with the treatment of deep sea divers many years ago. Today it is successfully used to treat a wide range of illnesses, injuries and chronic conditions. “Dozens of scientific papers will be presented by international specialists, who are making medical history using oxygen — in its many forms — for healing and sustaining life. This conference will feature the most focused group of oxygen specialists in the world,” said Dr. Donald L. Jolly-Gabriel, Ph.D., Chairman of the Richard A. Neubauer Research Institute, (RANRI) sponsors of the event. This is the 7th bi-annual symposium, presented by the institute.

Some 30 experts, using oxygen in the successful treatment of such diverse conditions as: traumatic brain injury, autism, cerebral palsy, lyme disease, spinal cord injury, alzheimer’s, stroke, diabetic wounds, multiple sclerosis, near-drowning, coma, anoxic encephalopathy, childhood mitochondrial diseases and more; will meet in Orange County, CA., for the first time. An exposition featuring some of the most advanced HBOT equipment and items in related fields will also be available to those in attendance.

“This forum provides a rare opportunity for the public to join the medical community in learning about break-through modalities in use here and abroad, to treat these serious conditions,” Jolly-Gabriel said. “Parents who are seeking alternative treatments for children with any of these conditions are urged to attend. They will interact doctors using HBOT and learn first-hand from and patients how HBOT has changed their prognosis and enhanced their lives.

“Oxygen is God’s gift to us,” Jolly-Gabriel added. “It is the single most important element necessary to sustain life. Although it is readily available everywhere, we are only now beginning to realize its true medical significance. It is a magnificent step forward in medicine.” The symposium will provide educational interaction with many of the world’s most eminent experts in the field.

OUTSTANDING SPEAKERS

Among featured speakers will be professor K. K. Jain, author of, “The Handbook of Hyperbaric Oxygen Therapy,” (now the “Textbook of Hyperbaric Medicine, currently in its fifth edition).” Jain is a retired professor and a highly respected consultant in neurology and hyperbaric medicine. He is also the author of more than 415 publications including 16 books on related topics.

Karen Simmons, CEO and founder of “Autism Today,” will be featured at an Author’s Luncheon Friday, July 23 at noon. Simmons, is the co-author of “Chicken Soup for the Soul, Children with Special Needs,” (co-authored with Jack Canfield, Mark Victor Hansen and Heather McNamara); and both “The Official Autism 101 Manual,” (an IPPY Gold Medal winner); and the recently released, “Autism Tomorrow, The Complete Guide to helping your Child Thrive in the Real World.”

Dr. Paul Harch, of the University of Louisiana Medical Center, who developed the HBOT protocol being used to restore the lives of American military personnel, following Traumatic Brain Injuries in combat, will be lauded for his work, during the symposium.

In addition, Some of the most recent studies conducted by world renowned brain specialist Dr. Daniel Amen, M.D., of Newport Beach, will also be presented.

 

WHO SHOULD ATTEND

HBOT 2010 is designed not only for medical professionals, but for or those who are affected by any of the conditions listed above, or involved in related associations, (i.e. the America Cancer Society, The Autism Society, the Multiple Sclerosis Society, etc.). The HBOT 2010 agenda includes new approaches in oxygen therapy for the treatment and management of these illnesses.

Attendance will be beneficial to medical professionals including: Neurologists, Pediatricians, Neonatologists, Perinatologists, Physical Therapists, Physiatrists, Orthopedic Surgeons and other professionals. It will afford them new insights into this remarkable medical option as well as practical applications for its use in conjunction with their specialties. Non-professionals such as: care-takers in coma recovery cases, stroke recovery or family members assisting people with disabilities, will also find this program beneficial. “We have done everything possible to make attending this conference exciting, convenient and affordable,” Jolly-Gabriel said. HBOT 2010 has negotiated a conference rate at the Irvine Marriott Hotel, of just $109 per night for those who register before June 15.

Register on-line at http://www.hbot2010.net/index.php. Or, visit the web site for additional information on the coming symposium, conference and exposition.

 (Medical writers and bloggers, affiliated recognized media outlets, are invited to cover the event)

Sharon Phillips

HBOT2010 – July 22-25 Marriott Hotel, Irvine, California

Tel: 954 540 1896

Fax: 954 827 0723

sharon@hbot2010.net

www.hbot2010.net

http://twitter.com/HBOT2010

VOLUME: 23 PUBLICATION DATE: Jan 01 2010

Sidebars_in_article: 
Issue Number: 

1 January 2010

   Hyperbaric oxygen therapy (HBOT) can be a valuable adjunctive treatment for patients with various types of wounds. These expert panelists discuss their indications for HBOT, their treatment protocol and barriers to the use of HBOT.

   Q: Do you use HBOT for your wound patients and what are the indications?

   A: As Caroline E. Fife, MD, explains, hyperbaric oxygen therapy is the administration of oxygen to the entire body at atmospheric pressures greater than 1.5 times sea level pressure. She notes one should not confuse this with topical oxygen administered to part of the body or oxygen (or air) via “zip up” chambers at very low atmospheric pressures. The usual treatment pressure for wound-related problems is at least 2.0 atmospheres absolute (ATA) although she notes that sometimes patients receive pressures of 2.4 or 2.5 ATA depending on the situation. At these pressures, one can expect tissue oxygen levels in excess of 600 mmHg.

   Dr. Fife notes hypoxia is a common cause of wound healing failure. Non-healing amputations, ulcers due to vascular insufficiency and diabetic foot wounds all share the problem of tissue hypoxia, which Dr. Fife says is usually due to ischemia from vascular disease.

   She says normalizing tissue PO2 enhances resistance to infection, collagen deposition and angiogenesis. However, Dr. Fife sees a disconnect between the rationale for HBOT and what physicians can treat in terms of current Medicare coverage policy.

    “While third-party payers require us to ‘bucket’ wounds and ulcers into neat diagnostic categories, real patients rarely cooperate by falling into clear disease classification systems,” explains Dr. Fife. “A variety of problem wounds exist and are usually the result of multiple local and systemic factors.”

   Kazu Suzuki, DPM, thinks HBOT is “an invaluable adjunctive therapy in modern wound care clinics.” He notes about 10 to 15 percent of his patients who present at his wound care centers have indications for HBOT and he recommends it routinely when indicated. Dr. Suzuki works with the three HBOT centers near his wound care clinic. Two of the centers have monoplace chambers while the other has a multi-place chamber that fits about 10 people at the same time.

   Dr. Suzuki has discovered that most patients prefer monoplace chambers because of the privacy with more open appointment times. This is in contrast to multi-place chamber clinics, which have a fairly rigid schedule for treatment, according to Dr. Suzuki. If the patient is five minutes late, he or she will miss the treatment. However, he always emphasizes that the efficacy of HBOT would be the same in either size chamber, since “oxygen is oxygen” regardless of which clinic they use.

   Michael DellaCorte, DPM, CHT, uses HBOT as an advanced treatment for patients with diabetes and says he has attained “very positive” results. He combines several treatment options with HBOT. These treatment options include negative pressure wound therapy (NPWT), PICC lines, Apligraf (Organogenesis) or Dermagraft (Advanced Biohealing) along with weekly wound care and offloading.

   Q: What are the indications for HBOT? When would you incorporate HBOT into your treatment protocol?

   A: Dr. Suzuki follows the guidelines of the Undersea Hyperbaric Medical Society (UHMS, www.uhms.org). Both he and Dr. DellaCorte use HBOT for diabetic foot ulcers of Wagner grade III or higher.

   In evaluating all the randomized controlled trials (RCTs) on diabetic foot ulcers over the past 10 years, Dr. Fife says only HBOT trials have enrolled patients with Wagner III grade ulcers and/or significant tissue ischemia. She points out that all other RCTs excluded patients with ischemia.1 Accordingly, Dr. Fife says HBOT “stands alone in demonstrating benefit for ischemic diabetic foot ulcers.”

   The Centers for Medicare and Medicaid Services (CMS) cover HBOT for diabetic foot ulcers based on the RCT data.2 As Dr. Fife maintains, while there is no reason to believe that HBOT would not be equally effective for ischemic ulcers in non-diabetics, HBOT is only “covered” for Wagner III diabetic foot ulcers and not for similar limb-threatening ulcers in patients without diabetes. She also notes that HBOT is covered for acute arterial ischemia.

   Drs. Suzuki and DellaCorte will use HBOT for patients with chronic osteomyelitis. Dr. Suzuki notes the synergy among most antibiotics and HBOT, adding that he uses magnetic resonance imaging to monitor treatment progress.

   Hyperbaric oxygen is also covered for chronic refractory osteomyelitis as it increases the oxygen concentration in bone, and directly kills or inhibits the growth of organisms that prefer low oxygen concentrations, according to Dr. Fife. She notes that HBOT also augments the antibacterial effect of certain antibiotics that have an oxygen dependent transport mechanism across the bacterial cell wall. Dr. Fife says these antibiotics include aminoglycosides, vancomycin, quinolones and certain sulfonamides.3

   Drs. Suzuki and DellaCorte also use HBOT for skin flap failure. When it comes to a transmetatarsal amputation, if the plantar skin flap does not heal properly, Dr. Suzuki immediately sends the patient for HBOT for skin flap salvage. He maintains that HBOT in this situation is far better than doing another proximal amputation. Dr. DellaCorte points out that transmetatarsal amputations that start to necrose do not do well with HBOT. Emphasizing that hyperbaric oxygen is not a substitute for revascularization, Dr. DellaCorte says he will refer the patient for bypass first if appropriate for the given patient.

   Dr. Fife says HBOT can help treat compromised flaps that appear to have post-op ischemia. She adds that HBOT can also help minimize the amount of tissue that does not survive after a plastic surgical “flap” and reduce the need for repeat flap procedures.4

   Dr. Suzuki and his partner, a plastic reconstructive surgeon, use HBOT for many cancer patients who have had radiation. Unless the patient received a very short course of radiation treatment, he says most radiation recipients suffer from radionecrosis of soft tissue (burn wound of skin to internal bleeding) and bone (spontaneous fracturing of jaw bone, etc).

    “This HBOT indication is often overlooked but we have made a lot of people happy by offering this treatment option,” says Dr. Suzuki.

   In regard to protocol, Dr. Suzuki starts with the initial consultation with the hyperbaric doctor on site and then prescribes 20 sessions of HBOT for wound indications such as diabetic foot ulcers. Each session is usually 60 to 90 minutes of 2.0 to 2.8 ATA, although each clinic has its own protocols. He says patients with osteomyelitis and radionecrosis indications usually need 30 sessions or more. It is rare but when it comes to traumatic amputation of toes, Dr. Suzuki would recommend twice daily HBOT treatment for a week after re-attachment of the digit and then may reduce that to once-a-day treatment.

   Although treatment varies according to the patient condition, Dr. DellaCorte says most patients receive 90 minutes of HBOT at a pressure of 2.4 ATA for a total time of about 106 minutes in the chamber, including eight minutes to get to the appropriate pressure and eight minutes to decompress. Six weeks or 30 dives/treatments is his standard protocol. As Dr. DellaCorte notes, CMS requires re-evaluation every 10 dives/treatments. If there is no improvement, he stops treatment but treatment will continue if the wound is improving.

   Dr. Fife uses transcutaneous oximetry to screen patients with non-healing wounds to determine if spontaneous healing is possible. If TcPO2 values are low and do not increase with sea level oxygen breathing, she says patients are likely to have vascular disease. She will perform revascularization when possible and subsequently reassess the TcPO2.5

   If values continue to be low and patients have a diagnosis for which HBOT would be covered, Dr. Fife performs in-chamber TcPO2 studies. As she notes, outcome studies suggest that 84 percent of diabetic foot ulcers with in-chamber values >200 mmHg are likely to respond to HBOT. Dr. Fife says treatment can be at 2.0 ATA or greater as long as in-chamber TcPO2 values are >200 mmHg.6 Dr. Fife says it is not clear whether the same in-chamber values are predictive of success for arterial ulcers or failing flaps. The average number of treatments for a DFU is around 35, says Dr. Fife. She notes that if patients fail to demonstrate benefit after 20 treatments, then HBOT should stop.

   Q: In your experience, what is the main barrier to treatment with HBOT?

   A: Dr. Suzuki notes one contraindication is untreated pneumothorax. However, Dr. Fife adds that one can treat pneumothorax if it is vented. Dr. Suzuki asks patients to refrain from getting the treatment when they have sinus congestion as high pressure may exacerbate the symptoms. If the patient is having a hard time clearing the ears during HBOT, both he and Dr. Fife suggest putting pressure equalization tubes in the patient’s ears.

   Dr. DellaCorte adds that ear barotrauma due to chamber pressure and claustrophobia are other barriers to treatment. Dr. Fife notes another relative contraindication includes pulmonary air trapping (chronic obstructive pulmonary disease). Patients with COPD are at risk for pulmonary barotrauma and Dr. Fife says one must decide whether it is safe for these patients to undergo HBOT. Patients with uncontrolled seizures are not recommended for HBOT, according to Dr. Fife.

   Dr. Suzuki’s patients sometimes complain of logistical problems since the ideal HBOT occurs Monday through Friday for 20 days, meaning four weeks of commitment. For out-of-town patients (commuting for an hour or longer) or dialysis patients, he recommends treatment three times a week (on non-dialysis days). Outcome data suggest that regular attendance to therapy affects whether patients benefit, according to Dr. Fife.7 She adds that therapy five days per week can be difficult for chronically ill patients.

   Dr. Suzuki refutes the claim that patients on VAC therapy (KCI) cannot be in the chamber. He says as long as the HBOT technicians know how to disconnect and reconnect the suction hose to keep the machine outside of the chamber, patients using VAC therapy can successfully undergo treatment with HBOT.

   Drs. DellaCorte and Fife note the barrier of insurance coverage. Although it is likely that non-diabetic patients with ischemia would benefit, Dr. Fife says in the absence of acute arterial insufficiency, a failing flap or osteomyelitis, patients whose only diagnosis is chronic arterial disease do not meet current coverage guidelines.

    “This is unfortunate since there are no other interventions likely to prevent limb loss if revascularization has failed to sufficiently increase tissue oxygen levels,” explains Dr. Fife.

   Research has shown that HBOT is cost effective in comparison to amputation and increases quality of life years.8,9 Dr. Fife notes the cost benefit of HBOT is enhanced by proper patient selection. Patients are best referred before tissue loss has progressed to the point where amputation is inevitable, says Dr. Fife. She notes that transcutaneous oximetry can be useful in screening out patients who are likely to get well without HBOT or patients who cannot be helped.

   Dr. Fife says one should not use HBOT as an alternative to proper revascularization. She says those on dialysis or those who have a transplant are less likely to benefit from HBOT, but are also less likely to benefit from any other intervention.

   Dr. Fife maintains that HBOT must be under the supervision of a properly trained advanced care practitioner who can manage complications.

    “When hyperbaric treatment is used in conjunction with standard wound care, researchers have demonstrated improved results in the healing of difficult or limb-threatening wounds in comparison to routine wound care alone,” she says.

Dr. DellaCorte is a Certified Hyperbaric Technologist. He is also a Fellow of the American College of Foot and Ankle Surgeons, and a Fellow of the American College of Foot and Ankle Orthopedics and Medicine. He is in private practice in Maspeth, N.Y.
Dr. Fife is an Associate Professor in the Department of Internal Medicine, Division of Cardiology at the University of Texas Health Science Center in Houston. She is the Director of Clinical Research at the Memorial Hermann Center for Wound Healing and Hyperbaric Medicine.

Dr. Suzuki is the Medical Director of Tower Wound Care Center at the Cedars-Sinai Medical Towers. He is also on the medical staff of the Cedars-Sinai Medical Center in Los Angeles and is a Visiting Professor at the Tokyo Medical and Dental University in Tokyo, Japan.

Editor(s): 

Kazu Suzuki, DPM, CWS

References: 

1. Carter MJ, Fife CE, Walker D, Thomson B. Estimating the applicability of wound-care randomized controlled trials to general wound care populations by estimating the percentage of individuals excluded from a typical wound care population in such trials. Adv Skin Wound Care 2009; 22(1):316-24.
2. Faglia E, Favales F, Aldeghi A, et al. Adjunctive systemic hyperbaric oxygen therapy in treatment of severe prevalently ischemic diabetic foot ulcer. Diabetes Care 1996;19(12):1338-1343.
3. Mader JT, Shirtliff ME, Calhoun JH. The use of hyperbaric oxygen in the treatment of osteomyelitis. In: Hyperbaric medicine practice. Best Publishing Co., Flagstaff, Arizona, 1999, pp. 603-616.
4. Zamboni WA. Applications of hyperbaric oxygen therapy in plastic surgery. In: Oriani G, Marroni A, Wattel F, eds. Handbook on hyperbaric oxygen therapy. Springer-Verlag, New York, 1996.
5. Fife CE, Smart DR, Sheffield PJ, Hopf HW, Hawkins G, Clarke D. Transcutaneous oximetry in clinical practice: consensus statements from an expert panel based on evidence. Undersea Hyperb Med 2009; 36(1):43-53.
6. Fife CE, Buyukcakir C, Otto GH, Sheffield PJ, Warriner RA, Love TL, Mader J. The predictive value of transcutaneous oxygen tension measurement in diabetic lower extremity ulcers treated with hyperbaric oxygen therapy; a retrospective analysis of 1144 patients. Wound Rep Regen 2002; 10(4):198-207.
7. Fife CE, Buyukcakir C, Warriner R, Sheffield P, Love T, Otto G. Factors influencing the outcome of lower extremity of diabetic ulcers treated with hyperbaric oxygen therapy. Wound Repair Regen 2007; 15(3):322-331.
8. Cianci P, Petrone G, Drager S, Lueders H, Lee H, Shapiro R. Salvage of the problem wound and potential amputation with wound care and adjunctive hyperbaric oxygen therapy: an economic analysis. J Hyperbaric Med 1988; 3:127-141.
9. Guo S, et al. Cost effectiveness of adjunctive hyperbaric oxygen in the treatment of diabetic ulcers. Int J Technol Assess Health 2003; 19(4):731-737.

Listen to Walter Wainright’s lecture by clicking the link below –

http://www.clickcaster.com/items/walter-wainright-lecture

Friends and colleagues please post a comment in support of DR HARCH’S pilot trial. Also please thank Congressman Jones for his support. Write whatever is appropriate for you individually. We would like Congressman Walter Jones to know there is a lot of energy surrounding and supporting this.

Here is the video below:

The AAHA, American Association for Hyperbaric Awareness, has been working quietly in the background for the last couple of years, representing your interests, namely, having hbot available to you when it is needed.

The AAHA does not represent any manufacturer or company trying to sell HBOT products.
The AAHA is not being used to sell chambers
The AAHA is not being used to promote any doctor or hbot center or to recruit business.
The AAHA has not made any promises or guarantees to you.
The AAHA has never asked you to pay any fees, dues, or contributions.
The AAHA is a 501 (c) 3 nonprofit organization dedicated to making America aware of the value of HBOT and the need to have insurance and Medicaid pay for hbot for brain injury or neurological conditions.
The AAHA is the only organization following a solid plan to bring HBOT to the forefront for anyone you know who may benefit.

The TV taping of a PBS program telling about the benefits of HBOT for neurological injury taking place in Feb. is the direct result of the AAHA’s efforts. This program will be aired in the Dallas-Ft. Worth area on PBS the end of Feb. It will be followed by PBS airing all over the USA in the weeks to follow.

Can you imagine the effect this can have on your chances of getting affordable HBOT in the future. With this type exposure, the chances of getting it approved for insurance coverage will be much stronger. Insurance companies will be viewing it and it can be used to convince them to cover your hbot.

Isn’t it about time we supported the AAHA? All you have to do to support them is join AAHASupporters@ yahoogroups. com. The strength is in numbers. If the AAHA can get this time of program across the USA and public officials and politicians begin to recognise HBOT, then we want the AAHA to continue to have the backing they need to get things done. If they know thousands of people are behind this effort they will listen. It is time for you to begin spreading the word to all your friends on all your email forums on how important it is to join the AAHA.

Remember, our strength lies in numbers. On the 2 main hbot groups, HBOTherapyforAutism and NeuroHBOT, we have almost 2400 families represented. If all of you would simple join the AAHA supporters group, when the time comes to write a letter, send an email, or take whatever action is needed in support of the AAHA, we can help them have the strength they need to be heard.

The AAHA has been in the background, now it is time to bring them to the forefront.

To join the AAHA, you can simply send a blank email to AAHAsupporters- subscribe@ yahoogroups. com or go the web page at http://health. groups.yahoo. com/group/ AAHAsupporters/

Thank you and please support the AAHA
Robert Hartsoe

I recently received the following paper from Professor Philip James.

“Oxygen Treatment for Children with Autism

Philip B James Emeritus Professor of Medicine, University of Dundee

Until the 1990s few children were labelled as ‘autistic’ and it is clear that the recent epidemic is not because of better diagnosis, it is because some aspect of the medical management of children at birth or in early childhood has changed.

The blood vessels of the brain are different to those in the rest of the body; they form a barrier because many substances present in blood are toxic. The barrier, known as the blood-brain barrier or ‘BBB’ needs energy to work properly and so is affected by lack of oxygen. Brain damage due to failure of the BBB can occur at any time during life but especially, as MRI has shown, at birth. After an initial insult the barrier may remain damaged as it is, for example, in multiple sclerosis patients.

Medical practice lags well behind the latest research findings about oxygen from biological scientists and oxygen is simply regarded as necessary for the production of energy. However, it has been shown that oxygen levels control genes including those responsible for new blood vessel formation, the control of inflammation and the release of stem cells into the circulation. These processes apply to the repair of all tissues but especially the brain.

Breathing is necessary to gain oxygen for normal function but also for recovery from injury or illness. Unfortunately, injury and disease involve blood vessels and this often restricts the delivery of oxygen just when it is most needed for repair Misunderstandings about the toxicity of oxygen have generally clouded judgement about the use of high levels in treatment. Enormous experience exists in aviation, space and underwater medicine about the safety of using oxygen in treatment.

To significantly increase the level of oxygen carried in the blood needs a pressure chamber and it is well-established, if not well-known, that giving a high level of oxygen for just one hour a day may promote the repair of tissues when all other medical interventions have failed. In other words giving more oxygen extends the envelope of natural recovery.

There is no substitute for oxygen and if giving more does not help a patient it is not because oxygen does not ‘work’ it is because the damage has gone too far to allow normal recovery. However, the key question is how many treatment sessions are needed and this is a difficult problem because the treatment is time consuming.

The original studies of oxygen treatment for multiple sclerosis sufferers used a course of 20 sessions and this number was also used for the controlled studies. Over the last 27 years the UK charity centres have also used an initial course of 20 sessions followed by weekly maintenance sessions because MS is a progressive illness. A course of 20 sessions on a daily basis for five days a week means that a course can be completed in a month. If assessment shows continued improvement the course can be repeated after a suitable interval and most centres report using a gap of four weeks. The evidence supports using oxygen by hood at 1.5 ata or 1.75 ata using a mask. However benefit has been reported at pressures as low as 1.3 ata with 24% oxygen. March 2009″

 

Paul G. Harch, M.D.
1816 Industrial Boulevard
Harvey, LA 70058
504-309-4948 or 504-366-1445
Fax: 504-366-1029
paulharchmd@aol.com

EDUCATIONAL  BACKGROUND

1976-1980

John Hopkins University School of Medicine
Doctor of Medicine, 1980

1972-1976

The University of California, Irvine
Bachelor of Science, Biology
Magna cum laude, Phi Beta Kappa

POSTGRADUATE  TRAINING

9/1987

13th Annual National Oceanographic and Atmospheric Administration Physician Diving Accident Medical Management Course, NOAA facility, Key Biscayne, Florida

7/1986 – 7/1987

Radiology resident, Louisiana State University School of Medicine, Charity Hospital, New Orleans, Louisiana

6/1986

Orientation course in Hyperbaric Oxygen Therapy and Wound Care, Long Beach Medical Center, Long Beach California

6/1980 – 12/1982

Two years general surgery training at the University of Colorado Health Sciences Center, Denver, Colorado, with six months leave for auto-ped accident

OTHER TRAINING

7/1/2004

LSU Animal Care Orientation Training for basic science investigators.

3/4/2002

Completion of self-certification course/Human Subjects Protection Educational Program for clinical investigators.

WORK EXPERIENCE

7/5/2005 – Present

Director, LSUHSC/Medical Center of Louisiana, New Orleans Hyperbaric Medicine and Wound Care Department

7/1993 – Present

Medical Director, LSU Hyperbaric Medicine and Wound Care Fellowship Program.  JoEllen Smith Medical Center (New Orleans, LA) 1993-5/1999, St. Charles General Hospital (New Orleans, LA) 5/1999-12/2004, West Jefferson Medical Center (Marrero, LA) 12/2004-present, Medical Center of Louisiana New Orleans 7/5/2005 – present.

Follow

Get every new post delivered to your Inbox.